Canaccord last night initiated coverage of Adma Biologics (ADMA) with a Buy rating and $21 price target The firm sees a favorable risk/reward at current share levels. The stock has been pressured on concerns about revenue recognition and true end-user demand for Adma’s key IVIG product Asceniv, but management commentary and positive key option leader feedback are supportive of solid growth and improving margins, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics initiated with a Buy at Canaccord
- Adma Biologics price target lowered to $24 from $30 at Mizuho
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Adma Biologics call volume above normal and directionally bullish
- ADMA Biologics Issues Rebuttal to Short-Seller Allegations